ATXA Therapeutics Ltd
- Biotech or pharma, therapeutic R&D
Based in Dublin, ATXA Therapeutics Ltd (ATXA) is a clinical stage pharma advancing drugs in the cardiovascular/cardiopulmonary/cardiometabolic area. Target is the Thromboxane Receptor (aka the TP), and lead drug is NTP42 (Phase II-ready), a small molecule antagonist of the human TP. Drugs are protected to 2036 by 16 patents, with others pending until 2045 globally.
NTP42 was successfully trialled in a Phase I & Bridging trials in 92 HVs, and ready for Phase II trials. We aim to focus on Group 1 (PAH), 2 (due to left heart disease) or 3 (due to iLDs) pulmonary hypertension (PH). ATXA has completed all Phase II-enabling work and positive feedback from both EMA & FDA on our trial plans, prior to regulatory filing for a multicentre Phase II clinical trial in PAH in 2025. ATXA seeks investment, partnership or other business co-development, licensing or M&A arrangements with strategically aligned VCs/pharma/biotech to participate in the continued clinical development of NTP42.
Address
University College DublinIreland
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}